Though MRNA has been generally overbought in the past few weeks, the market seems to be rejecting the low prices of the upper 130's. Fundamental speculators valuation is near 150, so we can expect a distinct bounce back in the upcoming days, and in addition to this, we expect good news regarding the FDA approving their vaccine as new public health data comes to light.
